PURPOSE: To obtain a new heterocyclic ketone prostaglandin analogue useful to treat thrombosis and angiospasm as a thromboxane A 2 receptor antagonist, a compound thromboxane A 2 receptor antagonist and a thromboxane synthetase inhibitor.
CONSTITUTION: This heterocyclic ketone prostaglandin analogue is a compd. represented by formula I [where (m) is 1-3; (n) is 0-3; X is O or NH; Y is O, a single bond, etc.; Z is CH=CH, (CH 2 ) 2 , etc.; R 1 is H, an alkyl, an aryl, etc.; and R 2 is CO 2 R or CONHSO 2 R 3 (R 3 is an alkyl, an aryl, etc.)], e.g. methyl [1S-(1α,2α,3α,4α)]-2-[[3-[4=(6-cyclohexyl-1-oxohexyl)-2-oxazolyl]-7- oxabicyclo[2,2,1]hept-2-yl]methyl]benzenepropionate. The compd. represented by formula I is produced from a bromophenylalkyl alcohol represented by formula II as starting material through a condensed 7-oxabicycloheptane compd. represented by formula III, etc.